An analysis from clinical trials and natural history studies showed a statistically significant difference in visual outcomes between Lumevoq-treated patients and untreated patients, according to a press release from GenSight Biologics.
In patients with Leber hereditary optic neuropathy, eyes treated with Lumevoq (GS010; lenadogene nolparvovec) showed progressive and sustained improvement from month 12 to month 52, while untreated eyes showed an “absence of recovery” over the same period. The difference became statistically significant at month 18 (P = .01). At month 48, the
Uncategorized